Skip to main content
Genetic testing may cut costs, overtreatment in early breast cancer

A 21-gene assay identified patients with early-stage, estrogen receptor-positive breast cancer who had a low risk of recurrence and could safely forgo adjuvant chemotherapy, reducing overtreatment and costs, researchers reported in the Journal of the National Comprehensive Cancer Network.

Full Story: